U.K.’s NICE says yes to Opdivo for advanced skin cancer

Eric Palmer

Last month the U.K. drug cost watchdog nixed Bristol-Myers Squibb's immunotherapy for use against lung , saying in draft guidance that it just cost too much to justify approval. But feels differently when it comes to using against cancer, today recommending it for approval without even extracting a price cut.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS